Beyond Biotech - the podcast from Labiotech

• Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play

  Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’?This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done. 01:14               Meet Gerard Caelles04:34               The Splice Bio platform12:34               Raising $135 million in uncertain times15:31               Laying the groundwork for a series B18:15               Building a fundraising team20:45               Identifying and approaching new investors22:38               Fundraising challenges in 202526:37               Refining the strategy and pitch29:00               Choosing lead investors 31:59               Keeping existing investors on board34:12               A look behind the scenes 37:52               What’s next for Splice Bio42:10               Learn more about Splice BioInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Labiotech's 2025 Biotech Funding TrackerThe ABC of biotech startup fundingBudget blues: where are cell and gene therapies heading? 

  --------  

  44:49

  --------

  44:49
• What’s next in immunology & inflammation R&D: The trends to watch

  Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying these innovations early is essential and, for university labs, spinouts and startups, getting their science in front of the right industry partners is key. So how does science meet industry, and how can top pharma and venture investors find the next blockbuster?This week I sat down with Joseph Ferner of Inpart, the author of a new R&D Trends Report on Immunology and Inflammation. He explained the shape of the research landscape, the areas that are generating the most interest amongst industry and investors, and the ways in which digital platforms are helping innovative scientists connect with those who have the experience and finance to bring their technologies and therapies to market.Download the Immunology & Inflammation R&D Trends ReportCreate a free Inpart Connect accountSpeak with the Inpart team02:18               The 2025 Immunology and Inflammation R&D Trends Report08:30               Priorities and challenges in immunology and inflammation research10:18               The impact of immune system complexity on drug development13:12               The challenge of clinical heterogeneity15:33               The role of organoids in immunology and inflammation R&D17:10               Comparing organoid models to animal models19:51               The R&D landscape in 202522:40               Popular modalities in immunology and inflammation research24:45               The top innovations in the 2025 R&D Trends Report28:56               How to score and rank innovations in a rapidly evolving market33:22               Engagement trends between researchers and industry partners37:09               Why companies decline to engage with academic researchers43:36               The Inpart Connect platform and how it works48:49               Looking forward to the next R&D Trends ReportInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Why is the immunology and inflammation market suddenly attracting a wave of investment?

  --------  

  51:25

  --------

  51:25
• BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year

  Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder that the biggest partnering events attract hundreds of innovators and thousands of attendees.One of the largest industry partnering events in Europe is BIOSPAIN. This year BIOSPAIN will take place in Barcelona, and the Catalan city will welcome participants from more than 40 countries for three days of exhibitions, partnering meetings, and presentations from industry leaders. Labiotech will be on the ground reporting from BIOSPAIN this year, and so we sat down with Stewart Medina fromBIOSPAIN to find out exactly what’s in store.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Catalonia: A biotech hub going from strength to strength, with Barcelona at its core10 biotech companies you should know about in Spain20 years of BIOSPAIN – The evolution of an international biotech event

  --------  

  44:54

  --------

  44:54
• AION Labs is building innovative biotechs with top pharma partners in Israel

  How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships?These are questions that this week’s guest, Mati Gill, CEO of AION Labs in Israel, is perfectly positioned to answer.AION Labs has an innovative company creation process that empowers scientists and startups to tackle high-impact pharma challenges with AI, backed by top-tier data, funding, and expertise from global pharma partners. In the middle of a transformative decade for AI-driven drug discovery, and with Israel poised to play an increasingly significant part, Mati explains how venture studios are helping to foster groundbreaking solutions for global health challenges.01:07               Meet Mati Gill07:19               The biotech industry in Israel09:38               How the Israeli biotech industry is changing with AI and other technologies13:01               The biggest challenges facing Israeli biotechs and biopharma18:07               AION Labs and its mission20:27               AION Building and AION Seeding24:03               Why top pharma wants to partner with AION Labs startups27:53               Workshopping startup ideas with top pharma companies32:04               The future of venture studios like AION Labs36:33               At the intersection of AI, biotech, and Israel’s innovation ecosystem39:24               Advice for entrepreneurs and scientistsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: AION Labs launches AI startup to improve drug trialsThe 5 hottest biotech companies making waves in IsraelWhat to look for in a biotech incubator

  --------  

  42:09

  --------

  42:09
• Navigating the biotech development journey from first steps to global scale with Lonza

  Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion. We sat down with Alice Harrison, Global Technical Director (CMC and Analytics), and Megan Mason, Global Process Development Implementation Manager, to learn more about how Lonza is helping innovators large and small develop and scale their therapies and deliver better outcomes for patients worldwide._____The information in this podcast is believed to be correct at the time of recording, and is for information only. While we make reasonable efforts to ensure that the content is accurate, we make no representations or warranties of any kind regarding its accuracy, completeness, reliability, suitability or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the reliance of the information contained herein is at your own risk.  _____Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: How to Set up Manufacturing for Biotech StartupsAccelerating the path to clinical filing applications with rapid toxicology material deliveryLarge molecule manufacturing: addressing challenges with strategies for success

  --------  

  50:40

  --------

  50:40

Więcej Wiadomości podcastów

Trendy w podcaście Wiadomości

O Beyond Biotech - the podcast from Labiotech